Introduction And Strategic Context

The Global Psychedelic API Market is set for substantial growth, projecting a CAGR of 14.8% . This market, valued at USD 1.9 billion in 2024 , is anticipated to expand to USD 4.3 billion by 2030 , according to Premier Market Insights.

 

Underpinning this trajectory, psychedelic APIs refer to pharmaceutical-grade active pharmaceutical ingredients derived from psychedelic compounds such as psilocybin, MDMA, LSD, DMT, mescaline, and ibogaine . These are manufactured under stringent regulatory conditions for therapeutic drug development, serving as the foundational raw materials for pharmaceutical companies, biotechnology firms, and clinical research organizations engaged in developing psychedelic-based treatments.

 

Driving this expansion, scientific interest in psychedelic-assisted therapy has resurged over the past decade, particularly for conditions like treatment-resistant depression, PTSD, addiction disorders, and anxiety-related illnesses . This renewed focus has spurred demand for a specialized upstream supply chain: the high-purity pharmaceutical API sector .

 

Shaping this landscape, the psychedelic API sector operates upstream from the development of psychedelic drugs. Biotech companies conducting clinical trials require GMP-certified APIs that meet rigorous regulatory standards. As more psychedelic therapeutics advance through Phase II and Phase III trials , the demand for reliable, scalable API manufacturing capabilities is rapidly increasing.

 

Compounding this demand, several macro forces are accelerating this trend between 2024 and 2030 .

• First, the global mental health burden is escalating . Hundreds of millions of patients worldwide suffer from depression, PTSD, and substance abuse disorders that often resist conventional treatments. Psychedelic-assisted therapies are increasingly being explored as next-generation neuropsychiatric interventions .
• Second, regulatory frameworks are gradually evolving . Nations like Australia, Canada, and certain regions within the United States are beginning to permit the controlled medical use of psychedelic compounds, thereby opening pathways for clinical trials and early commercialization.
• Third, significant investment is flowing into psychedelic drug development . Venture capital firms, pharmaceutical corporations, and institutional investors are actively supporting startups focused on psychedelic therapeutics, each requiring a consistent API supply for clinical trials and manufacturing scale-up.

At the same time, the stakeholder ecosystem is rapidly expanding. The psychedelic API market involves:

• Specialty pharmaceutical manufacturers producing GMP-grade psychedelic compounds
• Biotech firms developing psychedelic-based therapies
• Contract manufacturing organizations (CMOs) supporting synthesis and scale-up
• Clinical research organizations (CROs) conducting therapeutic trials
• Regulatory agencies defining drug approval pathways
• Investors and mental health foundations funding research

Beyond compliance, a notable shift is occurring in chemical production. While early psychedelic compounds were often extracted or synthesized in small laboratory batches, companies are now developing large-scale synthetic routes and biosynthetic production methods capable of meeting pharmaceutical manufacturing standards.

 

In essence, the psychedelic API market is transitioning from niche research chemistry to a structured pharmaceutical supply chain.

 

Looking ahead, if psychedelic therapies achieve regulatory approvals in the coming decade, API manufacturers will become a critical link in the value chain.

Market Segmentation And Forecast Scope

The Psychedelic API Market is evolving along multiple commercial and therapeutic dimensions. Unlike traditional pharmaceutical ingredient markets, psychedelic APIs are still closely tied to clinical research pipelines, regulatory approvals, and therapeutic experimentation . So segmentation reflects both chemical compounds and clinical applications .

From a strategic standpoint, the market can be segmented by Compound Type, Therapeutic Application, End User, and Region . Each of these layers represents a different stage in how psychedelic therapies move from laboratory synthesis to patient treatment.

By Compound Type

This is the most critical segmentation in the psychedelic API ecosystem because each compound has a distinct therapeutic pathway, regulatory status, and clinical trial activity level .

Psilocybin API
Psilocybin currently dominates the psychedelic API market. In 2024, psilocybin APIs account for roughly 34% of global API demand , primarily because multiple clinical trials are investigating psilocybin-assisted therapy for major depressive disorder, treatment-resistant depression, and anxiety disorders .

Most psilocybin APIs are produced through synthetic pharmaceutical-grade processes , although some companies are exploring biosynthetic fermentation methods.

 

MDMA API
MDMA APIs are gaining traction due to strong clinical evidence supporting MDMA-assisted psychotherapy for PTSD . Several Phase III clinical trials are nearing completion, which has pushed demand for high-purity MDMA APIs manufactured under GMP conditions .

This compound segment is expected to be one of the fastest-growing categories between 2024 and 2030 .

 

LSD API
LSD-based APIs are seeing renewed research interest, particularly in cluster headaches, depression, and anxiety disorders . However, regulatory complexity still limits the number of active LSD clinical programs compared to psilocybin or MDMA.

 

DMT and Derivatives
DMT-based APIs are being explored for rapid-acting antidepressant treatments due to their short psychedelic duration. Several biotech startups are engineering modified DMT molecules designed for therapeutic use in clinical environments.

 

Other Psychedelic APIs

This category includes compounds such as mescaline, ibogaine , and novel synthetic psychedelic analogs currently under early-stage investigation.

Many pharmaceutical companies are also developing proprietary psychedelic molecules that mimic the therapeutic mechanisms of classical psychedelics while reducing hallucinogenic intensity.

 

By Application

The demand for psychedelic APIs is directly tied to the clinical indications being targeted by drug developers .

Depression and Treatment-Resistant Depression
Depression is the largest application segment today, representing over 38% of clinical psychedelic research programs . Traditional antidepressants often require long treatment cycles, whereas psychedelic-assisted therapy aims to deliver rapid and sustained psychological benefits .

 

Post-Traumatic Stress Disorder (PTSD)
PTSD has emerged as a major focus area, particularly for MDMA-assisted psychotherapy . Military veterans, trauma survivors, and first responders represent large patient populations that conventional medications have struggled to treat effectively.

 

Substance Use Disorders
Psychedelic therapies are also being investigated for alcohol addiction, opioid dependence, and nicotine cessation . Several clinical studies suggest psychedelic experiences may help reset behavioral patterns linked to addiction .

 

Anxiety and End-of-Life Distress
Psychedelic-assisted therapy has shown promise in helping terminally ill patients manage existential anxiety and depression .

 

Other Neuropsychiatric Disorders
Additional research areas include obsessive-compulsive disorder, eating disorders, and chronic pain conditions .

 

By End User

Pharmaceutical and Biotechnology Companies
This group represents the largest buyers of psychedelic APIs , as they require large quantities of GMP-grade compounds for clinical development and eventual drug commercialization.

 

Contract Research Organizations (CROs)
CROs procure APIs to conduct clinical trials, pharmacological studies, and safety evaluations for pharmaceutical sponsors.

 

Academic and Research Institutes

Universities and neuroscience institutes continue to lead early-stage psychedelic research, particularly in neurobiology and therapeutic mechanisms .

 

Specialty Pharmaceutical Manufacturers
Some organizations purchase psychedelic APIs for formulation development and drug delivery system innovation .

 

By Region

North America
North America leads the psychedelic API market due to strong clinical research infrastructure, biotech investment, and progressive regulatory pilot programs .

 

Europe
Europe is expanding steadily, particularly through clinical research programs in the UK, Switzerland, and the Netherlands .

 

Asia-Pacific
Asia-Pacific remains a smaller but emerging market, driven by growing pharmaceutical manufacturing capabilities and expanding mental health awareness .

 

Latin America, Middle East, and Africa
These regions are currently limited in clinical development but may become important manufacturing and research hubs over time .

As psychedelic therapies move closer to regulatory approvals, segmentation will likely shift from research-focused demand to large-scale pharmaceutical manufacturing.

 

Market Trends And Innovation Landscape

The Psychedelic API Market is moving through a phase of scientific revival and pharmaceutical standardization. For years, psychedelic compounds existed largely within academic research labs. Today, the landscape is shifting toward industrial-scale manufacturing, advanced synthesis methods, and clinical-grade purity standards .

Between 2024 and 2030 , several innovation trends are shaping how psychedelic APIs are produced, optimized, and integrated into therapeutic drug pipelines.

Pharmaceutical-Grade Manufacturing is Becoming the Industry Standard

One of the most important developments is the transition from laboratory-scale synthesis to GMP-certified pharmaceutical manufacturing . Psychedelic compounds intended for therapeutic use must meet strict regulatory requirements for purity, stability, and batch consistency .

Specialized manufacturers are investing in:

• Controlled synthesis environments

• High-purity crystallization processes

• Analytical testing systems for impurity profiling

• Secure regulatory compliance infrastructure

This shift is transforming psychedelic chemistry into a regulated pharmaceutical supply chain .

Several manufacturers now operate dedicated GMP facilities designed specifically for controlled psychedelic compounds.

 

Biosynthesis and Fermentation-Based Production

Another emerging trend is the use of biosynthetic production techniques . Instead of traditional chemical synthesis, some companies are engineering microbial fermentation platforms capable of producing psychedelic molecules.

In this model, genetically modified yeast or bacteria produce compounds such as psilocybin through metabolic pathways similar to those found in nature.

The advantages include:

• More scalable manufacturing

• Lower production costs over time

• Reduced environmental footprint

• Higher batch consistency

This approach could significantly reduce manufacturing complexity once large-scale commercialization begins.

 

Development of Novel Psychedelic Analogs

Drug developers are also moving beyond classic psychedelics. Many biotech companies are designing next-generation psychedelic molecules that maintain therapeutic effects while modifying hallucinogenic properties.

These engineered APIs aim to achieve:

• Shorter therapeutic sessions

• Reduced psychoactive intensity

• Improved safety profiles

• Stronger intellectual property protection

In other words, pharmaceutical companies are attempting to create patentable psychedelic-inspired drugs rather than relying solely on naturally occurring compounds .

 

Advanced Drug Delivery and Formulation Research

Another important innovation area involves drug delivery optimization . Psychedelic APIs are being studied in multiple delivery formats including:

• Oral capsules

• Sublingual tablets

• Nasal sprays

• Intravenous formulations

Each delivery approach changes how quickly the compound acts and how long the therapeutic experience lasts.

Researchers are exploring ways to precisely control onset time and therapeutic duration , which could make psychedelic treatments easier to administer in clinical settings.

 

Increasing Clinical Trial Activity

The growing number of clinical trials is also accelerating innovation. Psychedelic APIs are now being tested in hundreds of clinical studies globally , covering a wide range of mental health conditions.

These trials are generating critical data on:

• Optimal dosing protocols

• Long-term safety profiles

• Therapeutic effectiveness

• Treatment session structures

As a result, pharmaceutical manufacturers are adjusting API production methods to support large-scale clinical research programs .

 

Strategic Partnerships Across the Ecosystem

Another defining trend is the emergence of collaboration networks across the psychedelic ecosystem.

Examples include partnerships between:

• Biotech firms and API manufacturers

• Universities and pharmaceutical companies

• Mental health institutes and drug developers

• Contract manufacturing organizations and research labs

These partnerships allow companies to accelerate research timelines and secure reliable API supply for clinical programs .

Many early psychedelic therapy startups have realized that securing a consistent pharmaceutical-grade API supplier is just as important as the therapy itself.

Overall, the psychedelic API market is moving rapidly from experimental chemistry toward regulated pharmaceutical infrastructure . As psychedelic therapeutics advance through clinical trials, innovation in API synthesis, formulation, and scalability will play a crucial role in determining how quickly these therapies reach patients.

 

Competitive Intelligence And Benchmarking

The Psychedelic API Market remains relatively concentrated but highly specialized. Unlike conventional pharmaceutical ingredients, psychedelic compounds require strict regulatory handling, controlled substance licensing, and highly specialized synthesis expertise . As a result, only a limited group of companies currently operate at pharmaceutical-grade manufacturing levels.

Competition in this market revolves around three core capabilities: GMP-certified manufacturing, scalable synthesis processes, and secure regulatory compliance . Companies that can consistently deliver high-purity psychedelic APIs while navigating controlled substance regulations are gaining early market leadership.

Below are several key players shaping the competitive landscape.

Compass Pathways

Compass Pathways is one of the most visible companies in the psychedelic therapeutics sector. The firm focuses heavily on psilocybin-based treatments for treatment-resistant depression .

Rather than positioning itself solely as a therapy developer, the company has invested significantly in proprietary psilocybin manufacturing capabilities . By controlling the API supply chain internally, Compass aims to maintain consistent compound quality across global clinical trials .

Their strategy revolves around integrating API production with clinical drug development , allowing tighter control over product formulation and dosing protocols.

 

Usona Institute

Usona Institute operates as a nonprofit research organization but plays an important role in the psychedelic API ecosystem. The institute produces pharmaceutical-grade psilocybin APIs used in clinical trials conducted by academic institutions and research hospitals.

Usona’s model is slightly different from commercial biotech firms. Instead of focusing on intellectual property, the organization prioritizes open scientific collaboration and clinical research expansion .

This approach has made Usona one of the key suppliers of psilocybin APIs for independent clinical research programs.

 

MindMed

MindMed is actively developing therapies based on compounds such as LSD derivatives and DMT analogs . The company works with specialized API manufacturers to ensure supply for its clinical development pipeline.

MindMed’s strategy focuses on engineering novel psychedelic molecules designed to maintain therapeutic benefits while improving safety and treatment predictability.

By investing in proprietary analog compounds, the company aims to create differentiated pharmaceutical assets that can be patented and commercialized globally .

 

Cybin Inc.

Cybin Inc. is emerging as a strong innovator in psychedelic drug development and API optimization. The company is exploring modified psychedelic compounds with shorter treatment durations and improved pharmacokinetic properties .

Cybin works closely with manufacturing partners to develop next-generation psychedelic APIs that enable controlled therapeutic experiences .

Their strategy centers on drug delivery innovation , combining psychedelic APIs with optimized formulation technologies.

 

Filament Health

Filament Health specializes in natural-source psychedelic APIs , particularly botanical psilocybin. The company has developed extraction and purification technologies that convert naturally derived psychedelic compounds into pharmaceutical-grade APIs suitable for clinical trials .

This natural-source strategy differentiates Filament from many competitors that rely solely on synthetic chemistry.

The company supplies psychedelic APIs to multiple research institutions and clinical trial sponsors worldwide.

 

Optimi Health

Optimi Health focuses on GMP-certified psychedelic API production , particularly psilocybin and MDMA. The company has invested in dedicated controlled substance manufacturing facilities designed to support clinical trials and early commercialization phases .

Optimi positions itself primarily as a pharmaceutical supply chain partner , providing high-purity APIs to biotech companies and research institutions.

 

Competitive Dynamics at a Glance

Several important dynamics define competition in the psychedelic API market:

• Vertical integration is increasing. Many psychedelic drug developers are attempting to control their API supply chain.

• GMP manufacturing capability is a major barrier to entry. Building compliant production facilities requires specialized licensing and regulatory approval.

• Patent strategies are becoming critical. Companies are increasingly developing modified psychedelic molecules that allow stronger intellectual property protection.

• Strategic partnerships are common. Drug developers frequently collaborate with contract manufacturers and research institutions.

At this stage, the market is less about mass production and more about establishing trusted pharmaceutical supply networks.

As psychedelic therapeutics approach potential regulatory approvals, companies that already operate scalable, compliant API production systems will likely hold a major competitive advantage.

 

Regional Landscape And Adoption Outlook

The Psychedelic API Market shows strong geographic variation due to differences in drug regulations, mental health policies, research infrastructure, and pharmaceutical manufacturing capabilities . While demand is global, the pace of adoption depends heavily on clinical trial activity and regulatory openness toward psychedelic-assisted therapies .

Below is a regional breakdown highlighting key adoption trends.

North America

North America currently represents the largest regional market , supported by strong biotech funding, clinical research activity, and progressive regulatory pilot programs .

Key factors driving regional growth include:

• The United States hosts the highest number of psychedelic clinical trials globally , creating sustained demand for GMP-grade APIs.

• Several U.S. states are exploring regulated therapeutic frameworks for psilocybin-assisted therapy , expanding future commercialization opportunities.

• Canada has become a major hub for psychedelic biotech startups and API manufacturers , supported by regulatory exemptions for medical research.

• Advanced pharmaceutical infrastructure allows large-scale GMP manufacturing of controlled substances .

North America also leads in venture capital investment into psychedelic medicine companies.

 

Europe

Europe represents the second-largest regional market , with steady growth driven by academic research institutions and progressive drug policy reforms .

Key market developments include:

• Countries such as Switzerland, the Netherlands, and the United Kingdom are conducting major psychedelic clinical research programs.

• European universities are leading several studies on psilocybin and LSD therapies for depression and anxiety disorders .

• Pharmaceutical companies in the region are increasingly collaborating with contract manufacturing organizations for psychedelic API production .

• Regulatory bodies in some European countries allow controlled medical access to psychedelic-assisted therapy under special programs .

Europe’s strong neuroscience research ecosystem is helping accelerate clinical validation of psychedelic treatments.

 

Asia Pacific

Asia Pacific is still an emerging market , but it holds significant long-term potential due to growing pharmaceutical manufacturing capacity and increasing mental health awareness .

Important regional trends include:

• Australia became one of the first countries to formally allow psychiatrists to prescribe psilocybin and MDMA for certain mental health conditions under regulated frameworks.

• Countries such as Japan, South Korea, and Singapore are expanding neuroscience and psychiatric research initiatives.

• Pharmaceutical manufacturers in India and China possess strong capabilities in API synthesis and large-scale drug manufacturing , which could eventually support psychedelic API production.

• Mental health care demand is rising rapidly across the region.

 

Latin America, Middle East, and Africa (LAMEA)

The LAMEA region remains early-stage in psychedelic research and therapeutic adoption , but several signals indicate gradual growth.

Key regional dynamics include:

• Brazil and Mexico are emerging as potential research hubs due to expanding psychiatric research programs.

• Some Latin American countries are exploring traditional psychedelic compounds such as ayahuasca and ibogaine for therapeutic research .

In the Middle East and Africa, regulatory frameworks remain strict, limiting commercial psychedelic development for now.

• International research collaborations may help introduce clinical trials and pilot programs in select countries.

 

Key Regional Insights

• North America leads global demand , supported by biotech investment and active clinical trial pipelines.

• Europe maintains strong academic leadership in psychedelic neuroscience research.

• Asia Pacific may become a future manufacturing hub for psychedelic APIs as regulations evolve.

• LAMEA markets remain largely untapped , offering long-term expansion potential once regulatory clarity improves.

Ultimately, regional growth will depend less on consumer demand and more on how quickly governments approve psychedelic therapies within regulated medical frameworks.

 

End-User Dynamics And Use Case

The Psychedelic API Market operates primarily within the pharmaceutical and clinical research ecosystem. Unlike traditional pharmaceutical ingredients that feed large-scale drug manufacturing immediately, psychedelic APIs are currently used mostly in research-driven environments, early therapeutic development programs, and regulated clinical trials .

End users in this market are typically organizations involved in drug discovery, psychiatric research, and experimental treatment protocols . Their purchasing decisions are strongly influenced by regulatory compliance, compound purity, and clinical trial requirements .

Below is how the major end-user groups interact with psychedelic APIs.

Pharmaceutical and Biotechnology Companies

Pharmaceutical and biotech companies represent the largest end-user segment in the psychedelic API market.

These organizations purchase psychedelic APIs primarily for:

• Clinical drug development programs

• Investigational new drug (IND) studies

• Phase I, II, and III clinical trials

• Formulation and drug delivery research

Many biotech firms developing psychedelic therapies rely heavily on consistent API supply chains to maintain standardized dosing in clinical trials. Even small variations in compound purity can affect therapeutic outcomes, making GMP-certified production a strict requirement .

Several psychedelic drug developers are also attempting vertical integration , where they either produce their own APIs internally or partner with dedicated API manufacturers.

For drug developers, the reliability of API manufacturing is as critical as the therapeutic research itself.

 

Contract Research Organizations (CROs)

CROs play a key operational role in psychedelic clinical trials. These organizations manage:

• Clinical trial execution

• Pharmacokinetic and pharmacodynamic studies

• Toxicology testing

• Regulatory documentation

To perform these tasks, CROs require pharmaceutical-grade psychedelic APIs supplied by licensed manufacturers.

Many biotech companies outsource clinical trial operations to CROs, which means CROs often handle API procurement and handling under controlled substance compliance protocols .

 

Academic and Research Institutes

Universities and neuroscience research centers continue to be major contributors to psychedelic science .

Academic institutions typically use psychedelic APIs for:

• Neuroscience research

• Psychiatric treatment studies

• Brain imaging and neuroplasticity research

• Mechanism-of-action investigations

These institutions often collaborate with government health agencies, nonprofit research organizations, and biotech companies to advance clinical understanding of psychedelic therapies.

Many of the early breakthroughs in psychedelic-assisted therapy are still emerging from university-led research programs.

 

Specialty Pharmaceutical Manufacturers

Some pharmaceutical companies purchase psychedelic APIs to develop final drug formulations and therapeutic delivery systems .

Their activities include:

• Capsule and tablet formulation

• Controlled-dose therapeutic products

• Stability and shelf-life testing

• Regulatory submission preparation

These manufacturers are preparing for a future where psychedelic therapies may become approved prescription treatments for mental health disorders .

 

Use Case Example

A tertiary psychiatric research center in Switzerland initiated a clinical trial investigating psilocybin-assisted therapy for treatment-resistant depression.

The institution partnered with a licensed psychedelic API manufacturer capable of supplying GMP-grade psilocybin . The API was formulated into standardized oral capsules and administered under carefully monitored therapeutic sessions.

Researchers observed measurable improvements in patient response rates compared to traditional antidepressant therapies. The standardized API supply allowed the research team to maintain consistent dosing across trial participants , which was essential for regulatory reporting and clinical validation.

Overall, the psychedelic API market remains research-driven today , but the role of end users is expected to evolve rapidly as psychedelic therapies move closer to commercial pharmaceutical approval .

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Several pharmaceutical-grade psilocybin production facilities have been commissioned in North America and Europe , expanding global capacity for GMP-certified psychedelic API manufacturing used in clinical trials.

• Multiple biotech companies advanced psychedelic-assisted therapies into late-stage clinical trials , particularly MDMA-based treatments for PTSD and psilocybin therapies targeting treatment-resistant depression.

• Strategic partnerships between psychedelic drug developers and contract manufacturing organizations increased , enabling scalable production of controlled psychedelic APIs under strict regulatory standards.

• Regulatory agencies in select countries introduced controlled therapeutic frameworks for psychedelic compounds , allowing psychiatrists to prescribe substances such as psilocybin and MDMA under regulated medical supervision.

• Biotechnology firms intensified research on next-generation psychedelic analogs , designed to deliver therapeutic benefits with shorter treatment durations and improved pharmacological control.

 

Opportunities

• Expansion of Psychedelic-Assisted Mental Health Therapies
  The rising prevalence of depression, PTSD, and substance use disorders is increasing demand for alternative treatment approaches. Psychedelic-assisted therapy has shown promising clinical outcomes, which could significantly expand the need for pharmaceutical-grade APIs.

• Growth of Clinical Research and Drug Development Pipelines
  A growing number of psychedelic drug candidates are progressing through clinical development stages. As more therapies enter Phase II and Phase III trials, demand for high-purity APIs will continue to increase.

• Emerging Manufacturing Innovations
  Advances in biosynthetic production, fermentation-based synthesis, and scalable chemical manufacturing are expected to reduce production costs and enable large-scale pharmaceutical supply of psychedelic APIs.

 

Restraints

• Strict Regulatory and Controlled Substance Restrictions
  Psychedelic compounds remain heavily regulated in many countries, which limits large-scale production, research access, and commercial development.

• Limited Manufacturing Infrastructure
  Only a small number of facilities currently possess the licensing and technical capabilities required to produce psychedelic APIs under pharmaceutical-grade GMP conditions.
   

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.9 Billion
Revenue Forecast in 2030	USD 4.3 Billion
Overall Growth Rate	CAGR of 14.8% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Compound Type, By Application, By End User, By Geography
By Compound Type	Psilocybin, MDMA, LSD, DMT and Derivatives, Others
By Application	Depression, PTSD, Substance Use Disorders, Anxiety and End-of-Life Distress, Others
By End User	Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, Specialty Pharmaceutical Manufacturers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, Netherlands, Switzerland, Australia, Japan, India, Brazil, etc.
Market Drivers	• Rising prevalence of mental health disorders globally • Increasing clinical trials exploring psychedelic-assisted therapy • Growing biotech investment in psychedelic drug development
Customization Option	Available upon request